Cellectis Sa News Today

Research Analysts’ new coverage for Sunday, May 5th: StockNews.com initiated coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY). They issued a sell rating on the stock. StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS). The firm issued a sell rating on the stock. StockNews.com began coverage on shares of ClearOne (NASDAQ:CLRO). They issued a buy rating […]

Investment Analysts’ new coverage for Saturday, September 2nd: StockNews.com initiated coverage on shares of Allied Motion Technologies (NASDAQ:AMOT). They issued a buy rating on the stock. StockNews.com initiated coverage on shares of Applied DNA Sciences (NASDAQ:APDN). The firm issued a hold rating on the stock. StockNews.com began coverage on shares of Avid Technology (NASDAQ:AVID). StockNews.com […]

08.02.2023 - NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) - Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and ... Seite 1

• Maximum Potential Dilution of Approximately 23.04%, Based on Share Capital of Cellectis as of September 30, 2022 NEW YORK, Jan. 04, 2023 -- Cellectis S.A. , a clinical-stage... | January 4, 2023

Equities Research Analysts’ upgrades for Friday, May 27th: Adams Resources & Energy (NYSE:AE) was upgraded by analysts at StockNews.com from a buy rating to a strong-buy rating. Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by analysts at StockNews.com from a sell rating to a hold rating. Cellectis (NASDAQ:CLLS) was upgraded by analysts at StockNews.com from a sell […]